Ixazomib is a proteasome inhibitor used with other medications to treat multiple myeloma in patients who have received one other therapy already. Because it is a modified peptide boronic acid with one chiral center, it is considered a boronate proteasome inhibitor.
- Mechanism
- Curator reviewed · 4 references
The ubiquitin-proteasome signalling pathway regulates cellular homeostasis and survival: It promotes protein degradation, activates the transcriptional factor nuclear factor (NF)-κB to upregulate the expression of growth and angiogenic factors, and blocks apoptosis. Made up of identical alpha (α)- and beta (β)-rings, the 20S proteasome catalytic core is part of the proteasome.
Ixazomib is a selective, potent, and reversible inhibitor of the 20S proteasome. It preferentially binds to the β5 chymotrypsin-like proteolytic site with a half-maximal inhibitory concentration (IC50) value of 3.4 nmol/L. At higher concentrations, ixazomib may inhibit the caspase-like (β1) and trypsin-like (β2) proteolytic sites.
- Primary indication
- Ixazomib is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.Curator reviewed · 1 structured indication
- Formula / weight
- C14H19BCl2N2O4 · 361.03 g/mol (avg)
- First approval
- Canada, 2016 · United States, 2015 · European Union, 2021
- Also known as
- ((1R)-1-((2,5-DICHLOROBENZAMIDO)ACETAMIDO)-3-METHYLBUTYL)BORONIC ACID · 2-[(1R)-1-[[2-[(2,5-dichlorobenzoyl)amino]acetyl]amino]-3-methylbutyl]-5-oxo-1,3,2-dioxaborolane-4,4-diacetic acid · BORONIC ACID, B-((1R)-1-((2-((2,5-DICHLOROBENZOYL)AMINO)ACETYL)AMINO)-3-METHYLBUTYL)-
- Code names
- MLN-2238
- Brand names
Resolves to
MXAYKZJJDUDWDS-LBPRGKRZSA-NSMILESCC(C)C[C@H](NC(=O)CNC(=O)C1=CC(Cl)=CC=C1Cl)B(O)OWhat you can answer from here — as of September 13, 2026
Which drugs share a target with Ixazomib, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account